

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of	)	
Barton, et al.	)	Attorney Docket No. PC31216
	)	
Serial No. 10/727,681	)	Group Art Unit: 1616
	)	
Filed: December 4, 2003	)	Examiner: B. Badio
For		
EPLERENONE CRYSTALLINE FORM EXHIBITING ENHANCED DISSOLUTION RATE		

May 23, 2006

Commissioner of Patents  
PO Box 1450  
Alexandria, VA 22313


SIR:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith a listing of various documents cited on the attached Form PTO 1449. Applicants direct the Examiner to the related application(s) for documents previously submitted. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

  
Robert S. Thomas, Reg. No. 52,284  
Attorney for Applicants  
(314) 274-4908 (St. Louis)

Pharmacia Corporation of Pfizer Inc  
Corporate Patent Department  
P.O. Box 1027  
Chesterfield, MO 63003

<b>FORM PTO-1449</b> U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE  <b>SUPPLEMENTAL INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET          NO.:</b> PC 031216	<b>APPLICATION NO.</b> 10/727,681
	<b>INVENTOR:</b> Barton, et al.	
	<b>Filed:</b> December 4, 2003	<b>Group:</b> 1616

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	4559332	12/17/85	Grob et al	514	175	4/9/84
	2	4826689	5/2/89	Violanto et al	424	489	5/17/85
	3	5145684	9/8/92	Liversidge et al	424	489	1/25/91
	4	5298262	3/29/94	Na et al	424	489	12/4/92
	5	5302401	4/12/94	Liversidge et al	424	501	12/9/92
	6	5336507	8/9/94	Na et al	424	489	12/11/92
	7	5340564	8/23/94	Illig et al	424	9	12/10/92
	8	5346702	9/13/94	Na et al	424	490	12/4/92
	9	5352459	10/4/94	Hollister et al	424	489	12/16/92
	10	5354560	10/11/94	Lovrecich	424	489	1/30/92
	11	5384124	1/24/95	Courteille et al	424	430	2/12/92
	12	5429824	7/4/95	June	424	489	12/15/92
	13	5503723	4/2/96	Ruddy et al	204	450	2/8/95
	14	5510118	4/23/96	Bosch et al	424	489	2/14/95
	15	5518187	5/21/96	Bruno et al	241	5	1/12/94
	16	5518738	5/21/96	Eickhoff et al	424	493	2/9/95
	17	5534270	7/9/96	De Castro	424	490	2/9/95
	18	5536508	7/16/96	Canal et al	424	501	10/21/93
	19	5552160	9/3/96	Liversidge et al	424	489	3/13/95
	20	5560931	10/1/96	Eickhoff et al	424	489	2/14/95
	21	5560932	10/1/96	Bagchi et al	424	489	1/10/95
	22	5565188	10/15/96	Wong et al	424	9.411	2/24/95
	23	5569448	10/29/96	Wong et al	424	9.45	1/24/95
	24	5571536	11/5/96	Eickhoff et al	424	489	2/6/95
	25	5573783	11/12/96	Desieno et al	424	490	2/13/95
	26	5580579	12/3/96	Ruddy et al	424	489	2/15/95
	27	5585108	12/17/96	Ruddy et al	424	434	12/30/94
	28	5587143	12/24/96	Wong	424	9.1	6/28/94
	29	5591456	1/7/97	Franson et al	424	494	2/10/95
	30	5665331	9/9/97	Bagchi et al	424	9.45	1/10/95
	31	5718919	2/17/98	Ruddy et al	424	489	2/24/95
	32	5747001	5/5/98	Wiedmann et al	424	45	2/24/95
	33	5981744	11/9/99	Ng et al	540	41	12/11/96
	34	5622938	4/22/97	Wong	514	35	
	35	5662883	9/2/97	Bagchi et al	424	9	

### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass
	36	WO 93/25190	12/23/93	PCT	A61K	9/14
	37	WO 96/24336	8/15/96	PCT	A61K	9/14, 9/51
	38	WO 96/24372	8/15/96	PCT	A61K	38/55
	39	WO 96/24373	8/15/96	PCT	A61K	38/55
	40	WO 96/40257	12/19/96	PCT	A61K	45/06, 31/585, 31/41
	41	WO 97/21720	6/19/97	PCT	C07J	21/00, 71/00, 53/00
	42	WO 98/25948	6/18/98	PCT	C07J	
	43	WO 98/35666	8/20/98	PCT	A61K	31/19, 9/14, 9/51, 9/20
	44	WO 00/51642	9/8/00	PCT	A61K	45/06

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	45	Agafonov et al (1991) Polymorphism of sprinolactone. Journal of Pharmaceutical Sciences 80 (2) 181-185
	46	Bonafede & Ward (1995) Selective nucleation and growth of an organic polymorph by ledge-directed epitaxy on a molecular crystal substrate. J. Amer. Chem. Soc. 117(30), 7853-7861
	47	Brittain (ed. 1999) Polymorphism in Pharmaceutical Solids (Marcel Dekker), pp 114-116, 207, 235, and 261.
	48	De Gasparo et al (1989) Antialdosterones: incidence and prevention of sexual side effects. J. Steroid Biochem. 32(1B), 223-227
	49	Grob et al (1997) Steroidal aldosterone antagonists: increased selectivity of 9 $\alpha$ , 11-epoxy derivatives. Helvetica Chemica Acta 80, 566-585
	50	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. Impurities: Guidelines for Residual Solvents. July 17, 1997
	51	Rabasseda et al (1999) Eplerenone. Drugs of the Future 24(5), 488-501

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	